Acute myeloid leukemia

Moleculin Biotech, Inc. Moleculin Biotech, Inc. INTERIM EFFICACY – N=45 INTENT TO TREAT (ITT) Both Annamycin dose arms…

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia…

Some therapies used to treat cancer may increase the risk of later developing cancers that affect the blood.…

By: Staff Writer | January 02, 2026 | 7 min. read | Share Summary A new study from Sylvester Comprehensive…

Jeffrey Tyner, Ph.D., and Melissa Stewart, Ph.D., led a team at OHSU that discovered a new drug combination…

Lagadinou ED, Sach A, Callahan K, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human…

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control